Product Datasheet

Trabodenoson

Catalog No. **BP-02213** · CAS **871108-05-3** · Form **free base** · Physical state **solid** · Color **White to yellow** · Version **1.0** · Revision **2026-09-07**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Adenosine Receptor	**Inflammation/Immunology**

Molecular formula	**$C_{15}H_{20}N_6O_6$**
Molecular weight	**380.3559**

STRUCTURE



DESCRIPTION

Trabodenoson (INO-8875), an adenosine mimetic, is a highly selective Adenosine A1 receptor agonist. Trabodenoson (INO-8875) is used in the study for Primary Open-Angle Glaucoma[1].

BIOLOGICAL ACTIVITY

In Vitro

Trabodenoson treatment significantly increaseS MMP-2 activity and MMP-14 abundance, while decreasing fibronectin and collagen IV expression.

In Vivo

Trabodenoson (6.0%), demonstrating an average IOP drop of 2.45 ± 0.38 mm Hg in young mice over 7 days (downregulation).

Topical trabodenoson significantly upregulates nestin expression in the ONH of induced eyes compared with vehicle-treated no-induced eyes.

Trabodenoson-treated eyes have significantly reduced optic nerve (ON) edema compared with vehicle-treated eyes. RGC counts are higher in Trabodenoson-treated eyes compared to vehicle (74% versus 47% of the contralateral eye).

SOLUBILITY

soluble in DMSO

REFERENCES

[1]. Guorong Li, et al. Trabodenoson, an Adenosine Mimetic With A1 Receptor Selectivity Lowers Intraocular Pressure by Increasing Conventional Outflow Facility in Mice. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):383-392.

[2]. Yan Guo, et al. Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION). Transl Vis Sci Technol. 2019 Dec 20;8(6):47.